Sudeep Pharma Ltd
SUDEEPPHRM NSE
Sudeep Pharma Ltd
HealthcareNSE: SUDEEPPHRM BSE: 544619 Pharmaceuticals & Biotechnology
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹12,752 Cr
Volatility
High Risk
P/E Ratio
65.69
EBITDA
₹251 Cr
Return on Equity
19.41%
Debt to Equity
0.17
Book Value
₹78.21
52W High
₹1,158.6
52W Low
₹524.05
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sudeep Pharma Ltd insights
47 extracted metrics + investor summaries across FY20–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company has delivered good profit growth of 39.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.8%
Weaknesses
1- Stock is trading at 14.1 times its book value
Growth Rate
Revenue Growth
31.19% ↗
Net Income Growth
25.67% ↗
Cash Flow Change
42.73% ↗
ROE
-31.00% ↘
ROCE
-30.38% ↘
EBITDA Margin (Avg.)
-4.18% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoAI opinion · based on fundamentals
Risk high
Sudeep Pharma Ltd is a small-cap healthcare company with a market cap of ₹126 Cr, trading at a PE of 64.8x and 13.5x book value. The company has delivered strong profit growth of 39% CAGR over 5 years and maintains a 3-year average ROE of 32%, though its current valuation multiples are significantly elevated relative to earnings.
Bull Case 7
- Strong 5-year compounded profit growth of 39% CAGR indicates consistent earnings momentum
- Robust 3-year ROE of 32% demonstrates efficient capital utilization well above industry averages
- 5-year compounded sales growth of 24% CAGR shows sustained top-line expansion
- TTM sales growth of 24% suggests continued revenue momentum in the most recent period
- TTM profit growth of 20% indicates the company continues to grow earnings in the latest period
- Last year ROE of 25% remains healthy and well above cost of equity for most Indian companies
- Operating in the pharmaceutical/healthcare sector which benefits from structural demand tailwinds in India
Bear Case 8
- PE ratio of 64.8x is extremely elevated, pricing in very high future growth expectations with limited margin of safety
- Price-to-book ratio of 13.5x is very high, suggesting the stock trades at a steep premium to its asset base
- Market cap of only ₹126 Cr classifies it as a micro-cap, exposing investors to liquidity risk and higher volatility
- TTM profit growth of 20% has decelerated significantly from the 5-year CAGR of 39%, indicating potential growth slowdown
- Last year ROE of 25% has declined from the 3-year average of 32%, suggesting diminishing return efficiency
- Dividend yield of just 0.14% provides negligible income return to shareholders
- Absence of disclosed debt-to-equity and EPS figures limits visibility into the company's leverage and per-share economics
- At 64.8x PE, even a modest earnings miss could trigger sharp price corrections given the demanding valuation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 3d ago Positives 2
- Q1FY26 profit jumps 30% YoY Aug 5
Consolidated net profit rose 29.8% YoY to ₹405.87 lakh in Q1FY26, driven by a 26% surge in revenue from pharmaceutical and nutrition segments.
- AGM approves battery expansion Aug 4
37th AGM adopted FY26 financials with ₹642.3 crore revenue and approved entry into advanced battery materials along with new board appointments.
Neutral 2
- Q1FY27 earnings call scheduled Jul 27
Sudeep Pharma will host an earnings call on August 5, 2026 at 11:00 AM IST with MD Sujit Bhayani to discuss Q1FY27 results.
- 37th AGM notice published Jul 13
Notice for 37th Annual General Meeting and e-voting details were published in newspapers on July 11, 2026.
TL;DR: Sudeep Pharma is delivering strong earnings growth with Q1FY26 profit up 30% YoY on robust revenue expansion. The company is diversifying into advanced battery materials, signaling ambitions beyond pharma. No visible headwinds in recent news flow. The upcoming Q1FY27 earnings call on Aug 5 will be key to confirming whether this growth trajectory is sustaining.
Quarterly Results
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 149 | 116 | 158 | 125 | 163 | 172 | 182 | 158 |
| Expenses | 85 | 76 | 99 | 81 | 107 | 112 | 120 | 103 |
| Operating Profit | 63 | 39 | 59 | 44 | 55 | 60 | 63 | 55 |
| OPM % | 43% | 34% | 37% | 35% | 34% | 35% | 34% | 35% |
| Other Income | 2 | 2 | 4 | 5 | 10 | 7 | 6 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 2 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| PBT | 62 | 38 | 58 | 44 | 60 | 62 | 63 | 54 |
| Tax % | 21% | 24% | 24% | 29% | 21% | 23% | 23% | 25% |
| Net Profit | 49 | 29 | 44 | 31 | 47 | 48 | 49 | 41 |
| EPS in Rs | 128 | 2.95 | 4.54 | 3.17 | 4.71 | 4.2 | 4.33 | 3.59 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 215 | 343 | 429 | 459 | 502 | 642 | 676 |
| Expenses | 98 | 171 | 276 | 338 | 276 | 310 | 419 | 443 |
| Operating Profit | 25 | 44 | 67 | 90 | 183 | 192 | 223 | 233 |
| OPM % | 21% | 20% | 20% | 21% | 40% | 38% | 35% | 34% |
| Other Income | 3 | 3 | 7 | 9 | 6 | 9 | 28 | 29 |
| Interest | 1 | 1 | 2 | 6 | 5 | 7 | 8 | 8 |
| Depreciation | 3 | 4 | 5 | 8 | 9 | 11 | 15 | 16 |
| PBT | 25 | 43 | 69 | 86 | 175 | 183 | 228 | 238 |
| Tax % | 27% | 22% | 27% | 28% | 24% | 24% | 24% | — |
| Net Profit | 18 | 33 | 50 | 62 | 133 | 139 | 174 | 184 |
| EPS in Rs | 128 | 237 | 356 | 442 | 945 | 14.27 | 15.31 | 16.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 1 | 10 | 11 |
| Reserves | 80 | 113 | 162 | 222 | 355 | 481 | 872 |
| Borrowings | 20 | 31 | 84 | 83 | 78 | 140 | 150 |
| Other Liabilities | 30 | 67 | 97 | 113 | 80 | 86 | 141 |
| Total Liabilities | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
| Fixed Assets | 60 | 68 | 137 | 158 | 180 | 189 | 337 |
| CWIP | 8 | 24 | 8 | 26 | 45 | 88 | 185 |
| Investments | 6 | 19 | 0 | 3 | 0 | 0 | 0 |
| Other Assets | 57 | 102 | 199 | 232 | 289 | 439 | 652 |
| Total Assets | 131 | 213 | 344 | 420 | 514 | 717 | 1,174 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | 10 | 35 | -3 | 48 | 66 | 49 | 70 |
| Investing | -22 | -40 | -38 | -50 | -49 | -79 | -327 |
| Financing | 12 | 13 | 51 | -10 | -13 | 53 | 247 |
| Net Cash Flow | 0 | 8 | 10 | -11 | 4 | 23 | -10 |
| Free Cash Flow | 1 | 24 | -77 | 1 | 13 | -15 | -49 |
| CFO/OP | 62 | 104 | 22 | 78 | 60 | 47 | 56 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 94 | 114 | 80 | 115 | 135 | 129 |
| Inventory Days | 77 | 79 | 104 | 142 | 147 | 309 | 356 |
| Days Payable | 70 | 79 | 76 | 77 | 112 | 145 | 113 |
| Cash Conversion Cycle | 97 | 93 | 142 | 145 | 150 | 298 | 372 |
| Working Capital Days | 46 | 13 | 30 | 92 | 99 | 144 | 175 |
| ROCE % | — | 36% | 36% | 33% | 49% | 36% | 28% |
Documents
2
Closure of Trading Window
26 Mar - Trading window closed from 1 Apr 2026 until 48 hours after FY2026 audited results declaration. 26 Mar - Trading window closed from 1 Apr 2026 until 48 hours after FY2026 audited results declaration.
Frequently Asked Questions about Sudeep Pharma Ltd
What does Sudeep Pharma Ltd do?
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]
Where is Sudeep Pharma Ltd (SUDEEPPHRM) listed?
Sudeep Pharma Ltd is listed on the Indian stock exchanges. It is listed on NSE: SUDEEPPHRM and BSE: 544619. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sudeep Pharma Ltd belong to?
Sudeep Pharma Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sudeep Pharma Ltd?
Sudeep Pharma Ltd has a market capitalisation of approximately ₹12751.90 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Sudeep Pharma Ltd?
The Price-to-Earnings (PE) ratio of Sudeep Pharma Ltd is 65.69. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sudeep Pharma Ltd?
Over the past 52 weeks, Sudeep Pharma Ltd has traded between a low of ₹524.05 and a high of ₹1,158.6. This range helps investors understand the stock's price volatility and recent trading levels.
Does Sudeep Pharma Ltd pay dividends?
Yes, Sudeep Pharma Ltd has a dividend yield of 0.14%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Sudeep Pharma Ltd?
Sudeep Pharma Ltd has a Return on Equity (ROE) of 19.41%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sudeep Pharma Ltd on Tapetide?
On Tapetide, you can view Sudeep Pharma Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1989, Sudeep Pharma Limited is a manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients serving over 100 countries.[1]